Hims & Hers Health (HIMS) News Today

Hims & Hers Health, Inc. (NYSE: HIMS) shares have decreased amid a mixed post-earnings outlook. Investors are weighing strong revenue growth and higher guidance against lower margins, an earnings miss, and growing legal scrutiny.

• Positive Sentiment: Management raised its full-year revenue outlook to approximately $3.1 billion–$3.3 billion, while second-quarter revenue increased 38% year over year to $753.2 million. The guidance suggests continued demand for Hims & Hers’ telehealth and weight-management offerings. Hims & Hers Raised Guidance
• Positive Sentiment: Bank of America and Needham analysts reportedly maintained constructive views on HIMS, supporting the bullish case that subscriber growth, expanding services, and the company’s longer-term healthcare platform can outweigh near-term volatility. Bank of America Analyst Forecast Needham Analyst Forecast
• Neutral Sentiment: Analyst opinion is divided: Citigroup issued a more pessimistic forecast, highlighting valuation and execution risks as Hims & Hers transitions its weight-loss business. Citigroup Forecast
• Negative Sentiment: The company’s gross margin fell six percentage points sequentially to 64% as branded GLP-1 drugs increased revenue but produced less favorable economics. The earnings report also included an adjusted loss of $0.37 per share, substantially below the $0.05 loss analysts expected, increasing concerns that growth is coming at the expense of profitability. Hims & Hers Margin Analysis
• Negative Sentiment: Several law firms, including Kaplan Fox, Kessler Topaz, Glancy Prongay Wolke, and Howard G. Smith, announced investigations into potential securities-law violations. These announcements are investor-solicitation notices rather than findings of wrongdoing, but they add headline, litigation, and reputational risk following the Federal Trade Commission’s lawsuit against the company. Kaplan Fox Investigation Kessler Topaz Investigation